To demonstrate the potential of this strategy in the identification of novel genetic interaction partners of major cancer driver genes, we experimentally validated the predicted synthetic lethality partners of PIK3CA using CRISPR/Cas9 knockout screening as a case study of potential anticancer treatments for PIK3CA driven cancers. This evidence concerns the gene PIK3CA and cancer.